Catheter-directed Venous Thrombolysis (CaVenT) in Acute Iliofemoral Vein Thrombosis - an open Randomized, Controlled, Clinical Trial - CaVenT

Eastern Norway Regional Health Authority0 sites200 target enrollmentNovember 4, 2005

Overview

No summary available.

Registry

who.int

Start Date

November 4, 2005

End Date

TBD

Last Updated

10 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

Eastern Norway Regional Health Authority

•1 Age 18\-75 years.
•2 Onset of symptoms \<21 days.
•3 Objectively (ultrasonography, venography, computer tomography, or magnetic resonance imaging) verified DVT of the femoral or common iliac veins or the combined iliofemoral segment.
•4 Informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range

•1 Anticoagulant therapy prior to trial entry for \>7 days.
•2 Contraindications to thrombolytic therapy, including bleeding diathesis.
•3 Indications for thrombolytic therapy, e.g., phlegmacia coerolia dolens or vena cava thrombosis.
•4 Severe anemia (hemoglobin \<8 g/dL).
•5 Thrombocytopenia (platelets \<80•109/L).
•6 Severe renal failure – creatinine clearance \<30 ml/min.
•7 Severe hypertension, i.e. persistent systolic blood pressure \>160 mm Hg or diastolic blood pressure \>100 mm Hg.
•8 Pregnancy (but post\-partum thrombosis may be included).
•9 Less than 14 days post\-surgery or post\-trauma.
•10 History of subarachnoidal or intracerebral bleeding.